HIGHLIGHTS
SUMMARY
Oral administration compared to the intra-venous route exhibits superior patient compliance and non-invasiveness; these characteristics are particularly advantageous in heavily pre-treated patients and later lines of treatment. There are neither molecular nor clinical characteristics guiding the use of TAS-102 or regorafenib first in the late treatment of mCRC patients. Lacking head-to-head comparisons, this study was undertaken to explore any differences between the efficacy of two different therapy sequences including TAS-102 or regorafenib first (TAS-102 before regorafenib versus regorafenib before TAS-102) in a real practice clinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.